权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Development of novel drugs against an untreated common target in multiple cancers

针对多种癌症中未经治疗的共同靶标开发新药

基本信息

批准号：
10001247
负责人：
金额：
$ 34.83万
依托单位：
APOBEC DISCOVERY LTD
依托单位国家：
英国
项目类别：
Feasibility Studies
财政年份：
2021
资助国家：
英国
起止时间：
2021 至无数据
项目状态：
已结题

来源：
https://gtr.ukri.org/projects?ref=10001247
关键词：
Development novel drugs against untreated

项目摘要

APOBEC proteins have been recently recognised as the most significant cause of cancer, even more so than smoking or UV radiation. The genetic mutations driven be APOBEC are not only the cause and growth of many common cancers, but also their spread and the development of drug treatment resistance in the cancer. There are currently no medical treatments approved or in clinical development targeting this fundamental cancer driver. APOBEC Discovery Limited (ADL) is developing novel treatments to inhibit the harmful activity of these proteins to create a completely new class of anti-cancer therapy. A safe and effective APOBEC-inhibiting drug should have a broad range of activity across a number of common cancers: preventing growth, spread and treatment resistance. It may also have potential opportunity to be utilised to prevent cancers forming in high-risk individuals. ADL has developed a set of lead candidate molecule drugs that are expected to show significant activity against cancer cells in the laboratory. This project will facilitate the development of proof of concept in in vivo models allowing ADL to generate safety and efficacy data for our lead drug candidates. This data will enable ADL to optimise late stage pre-clinical development prior to first human studies. Only one of the top selling cancer medicines globally is being commercialised by a UK pharmaceutical company. ADL's goal is that this significant drug research programme helps cancer patients live longer.

APOBEC 蛋白最近被认为是导致癌症的最重要原因，甚至比吸烟或紫外线辐射更重要。 APOBEC驱动的基因突变不仅是许多常见癌症的起因和生长，而且是它们的扩散和癌症耐药性的发展。目前还没有针对这一基本癌症驱动因素的治疗方法获得批准或处于临床开发阶段。 APOBEC Discovery Limited (ADL) 正在开发新的治疗方法来抑制这些蛋白质的有害活性，以创造一种全新的抗癌疗法。一种安全有效的 APOBEC 抑制药物应该对多种常见癌症具有广泛的活性：防止生长、扩散和治疗耐药。它还可能有潜在机会用于预防高危人群癌症的形成。 ADL 开发了一系列主要候选分子药物，预计在实验室中对癌细胞表现出显着的活性。该项目将促进体内模型概念验证的开发，使 ADL 能够为我们的主要候选药物生成安全性和有效性数据。这些数据将使 ADL 能够在首次人体研究之前优化后期临床前开发。全球最畅销的抗癌药物中只有一种由英国制药公司进行商业化。 ADL 的目标是这一重要的药物研究项目帮助癌症患者延长寿命。